Ismael R. Ortega-Sanchez
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Ismael R. Ortega-Sanchez has a total of 29 co-authors. Here are the top co-authors by number of shared publications:
Albert E. Barskey
Centers for Disease Control and Prevention (CDC), National Center for Immunization and Respiratory Diseases, 1600 Clifton Road, Ne MS-A-34, Atlanta, GA 30333, USA
1 shared publicationAmanda Cohn
1 shared publicationAmy Cassedy
1 shared publicationCarolyn Bridges
1 shared publication- Diana L. Bartlett
Immunization Services Division, National Center for Immunization and Respiratory Diseases, Centers for Disease Control and Prevention, Atlanta, Georgia 30333, USA
1 shared publication Elizabeth Zell
1 shared publication
Latest Publications
- Open Access
The economic burden of sixteen measles outbreaks on United States public health departments in 2011
- 1 October 2009
- Published by Oxford University Press (OUP) in Clinical Infectious Diseases
- Vol. 49 (7) , 1137
Reply to Crépey and Getsios
- 1 October 2009
- Published by Oxford University Press (OUP) in Clinical Infectious Diseases
- Vol. 49 (7) , 1137
Reply to Crépey and Getsios
- Open Access
- 15 March 2008
- Published by Oxford University Press (OUP) in Clinical Infectious Diseases
- Vol. 46 (s3) , S168-S178
Economics of Cardiac Adverse Events after Smallpox Vaccination: Lessons from the 2003 US Vaccination Program
Of >39,000 civilian public health responders vaccinated against smallpox in 2003, 203 reported cardiovascular adverse events (CAEs). An associatio
- 15 March 2008
- Published by Oxford University Press (OUP) in Clinical Infectious Diseases
- Vol. 46 (s3) , S168-S178
Open AccessEconomics of Cardiac Adverse Events after Smallpox Vaccination: Lessons from the 2003 US Vaccination Program
Of >39,000 civilian public health responders vaccinated against smallpox in 2003, 203 reported cardiovascular adverse events (CAEs). An associatio
- 1 January 2008
- Published by American Academy of Pediatrics (AAP) in Pediatrics
- Vol. 121 (Supplement) , S63-S78
Projected Cost-effectiveness of New Vaccines for Adolescents in the United States
BACKGROUND. Economic assessments that guide policy making on immunizations are becoming increasingly important in light of new and anticipated vaccines for adolescents. However, important considerations that limit the utility of these assessments, such as the diversity of approaches used, are often overlooked and should be better understood.OBJECTIVE. Our goal was to examine economic studies of adolescent vaccines and compare cost-effectiveness outcomes among studies on a particular vaccine, across adolescent vaccines, and between new adolescent vaccines versus vaccines that are recommended for young children.METHODS. A systematic review of economic studies on immunizations for adolescents was conducted. Studies were identified by searching the Medline, Embase, and EconLit databases. Each study was reviewed for appropriateness of model design, baseline setup, sensitivity analyses, and input variables (ie, epidemiologic, clinical, cost, and quality-of-life impact). For comparison, the cost-effectiveness outcomes reported in key studies on vaccines for younger children were selected.RESULTS. Vaccines for healthy adolescents were consistently found to be more costly than the health care or societal cost savings they produced and, in general, were less cost-effective than vaccines for younger children. Among the new vaccines, pertussis and human papillomavirus vaccines were more cost-effective than meningococcal vaccines. Including herd-immunity benefits in studies significantly improved the cost-effectiveness estimates for new vaccines. Differences in measurements or assumptions limited further comparisons.CONCLUSION. Although using the new adolescent vaccines is unlikely to be cost-saving, vaccination programs will result in sizable health benefits.
- 1 January 2008
- Published by American Academy of Pediatrics (AAP) in Pediatrics
- Vol. 121 (Supplement) , S63-S78
Projected Cost-effectiveness of New Vaccines for Adolescents in the United States
BACKGROUND. Economic assessments that guide policy making on immunizations are becoming increasingly important in light of new and anticipated vaccines for adolescents. However, important considerations that limit the utility of these assessments, such as the diversity of approaches used, are often overlooked and should be better understood.OBJECTIVE. Our goal was to examine economic studies of adolescent vaccines and compare cost-effectiveness outcomes among studies on a particular vaccine, across adolescent vaccines, and between new adolescent vaccines versus vaccines that are recommended for young children.METHODS. A systematic review of economic studies on immunizations for adolescents was conducted. Studies were identified by searching the Medline, Embase, and EconLit databases. Each study was reviewed for appropriateness of model design, baseline setup, sensitivity analyses, and input variables (ie, epidemiologic, clinical, cost, and quality-of-life impact). For comparison, the cost-effectiveness outcomes reported in key studies on vaccines for younger children were selected.RESULTS. Vaccines for healthy adolescents were consistently found to be more costly than the health care or societal cost savings they produced and, in general, were less cost-effective than vaccines for younger children. Among the new vaccines, pertussis and human papillomavirus vaccines were more cost-effective than meningococcal vaccines. Including herd-immunity benefits in studies significantly improved the cost-effectiveness estimates for new vaccines. Differences in measurements or assumptions limited further comparisons.CONCLUSION. Although using the new adolescent vaccines is unlikely to be cost-saving, vaccination programs will result in sizable health benefits.
- Open Access
- 1 January 2006
- Published by Springer Nature in Cost Effectiveness and Resource Allocation
- Vol. 4 (1) , 1-15
Economics of immunization information systems in the United States: assessing costs and efficiency.
One of the United States' national health objectives for 2010 is that 95% of children aged <6 years participate in fully operational population-based immunization information systems (IIS). Despite important progress, child participation in most IIS has increased slowly, in part due to limited economic knowledge about IIS operations. Should IIS need further improvement, characterizing costs and identifying factors that affect IIS efficiency become crucial.
- 1 January 2006
- Published by Springer Nature in Cost Effectiveness and Resource Allocation
- Vol. 4 (1) , 1-15
Open AccessEconomics of immunization information systems in the United States: assessing costs and efficiency.
One of the United States' national health objectives for 2010 is that 95% of children aged <6 years participate in fully operational population-based immunization information systems (IIS). Despite important progress, child participation in most IIS has increased slowly, in part due to limited economic knowledge about IIS operations. Should IIS need further improvement, characterizing costs and identifying factors that affect IIS efficiency become crucial.